Prof Joensuu speaks at a SABCS 2017 press session about data from the phase III Synergism or Long Duration (SOLD) clinical trial.
Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment.
Read the news story for more.